跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/jRCT2032240613
jRCT2032240613招募中不适用

Prospective, multi-center, single-arm investigational study of SWM-831 to treat moderate and severely calcified femoropopliteal arteries (CP 71411)

Shockwave Medical, Inc.0 个研究点目标入组 60 人开始时间: 2025年3月17日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
招募中
入组人数
60
主要终点
Femoropopliteal Procedural success
研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 No limit（—）
性别
All

入选标准

  • •General Inclusion Criteria
  • •Subject is able and willing to comply with all assessments in the study.
  • •Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.
  • •Age of subject is >=
  • •Note: If a subject is under 20 years, voluntary agreement shall be obtained from both the subject and the subject's representative or legal guardian using the written consent form.
  • •Rutherford Clinical Category 2, 3, 4, or 5 of the target limb.
  • •Estimated life expectancy > 1 year.
  • •Angiographic Inclusion Criteria
  • •One target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery).
  • •<Not applicable to iliac or BTK cohort>
  • •Target lesion reference vessel diameter (RVD) is between 4.0 mm and 8.0 mm by investigator visual estimate. <Not applicable to iliac or BTK cohort>
  • •Target lesion with >= 70% stenosis by investigator visual estimate.
  • •Target lesion length is <= 200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.
  • •Subject has at least one patent tibial vessel on the target limb with runoff to the foot, defined as no stenosis >= 50%.
  • •Calcification is determined to be grade 2 - 4 (unilateral calcification >= 5 cm, bilateral wall calcification < 5 cm, and bilateral calcification >= 5 cm, respectively), as defined by PACSS (Peripheral Artery Calcification Scoring System). <Not applicable to iliac or BTK cohort>
  • •Angiographic Inclusion Criteria specific to Iliac Arteries
  • •Target lesion located in the native, de novo common or external iliac artery.
  • •Target lesion reference vessel diameter (RVD) is between 5.0 mm and 10.0 mm by investigator visual estimate.
  • •Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
  • •Note: Non-dilatable lesion requires attempted treatment with Percutaneous Transluminal Angioplasty (PTA) during the index procedure with residual stenosis >= 50% and no serious angiographic complication.
  • •Angiographic Inclusion Criteria specific to BTK Arteries
  • •Target lesion from the native, de novo distal segment of the popliteal artery to the ankle joint.
  • •Target lesion reference vessel diameter (RVD) is between 2.0 mm and 4.0 mm by investigator visual estimate.
  • •Evidence of PACSS calcification grade 2 - 4 and non-dilatable lesion indicating presence of calcium.
  • •Note: Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis >= 50% and no serious angiographic complication.

排除标准

  • •General Exclusion Criteria
  • •Rutherford Clinical Category 0, 1 and
  • •Subject has known or suspected active infection evidenced by WBC
  • •> 14.0 (14000/mm3) within 14 days prior to index procedure.
  • •Previous or planned target limb major amputation (above the ankle).
  • •History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.
  • •Note: Inflow treatment of non-target lesions is allowed provided successful treatment.
  • •Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
  • •Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pretreated.
  • •Subject has known allergy to urethane, nylon, or silicone.
  • •History of myocardial infarction within 60 days prior to enrollment.
  • •History of stroke within 60 days prior to enrollment.
  • •History of thrombolytic therapy within two weeks prior to enrollment.
  • •Subject has acute or chronic renal disease with creatinine >= 2.5 mg/dL, unless on dialysis.
  • •Subject is pregnant or nursing.
  • •Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
  • •Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and posttreatment.
  • •The use of specialty balloons, re-entry or atherectomy devices.
  • •Active COVID-19 or previously diagnosed COVID-19 with sequelae that could confound endpoint assessments.
  • •Subject has an anticipated life span of less than one (1) year.
  • •General Exclusion Criteria specific to BTK Arteries
  • •Subjects with osteomyelitis or deep soft tissue infection in the target limb.
  • •Acute limb ischemia (of either leg).
  • •Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot) in the target limb.
  • •Angiographic Exclusion Criteria
  • •In-stent restenosis within 10 mm of the target lesion.
  • •Lesion within 10 mm of the ostium of the SFA or within 10 mm proximal to the anterior tibial artery ostium. <Not applicable to iliac or BTK cohort>
  • •Evidence of aneurysm or thrombus in target vessel.
  • •No calcium or mild calcium in the target lesion by PACSS.
  • •Target lesion within native or synthetic vessel grafts.
  • •Subject has significant stenosis (>= 50% stenosis) or occlusion of inflow tract before target treatment zone (e.g., iliac or common femoral) not successfully treated.
  • •Failure to successfully treat significant distal non-target lesions, if treated prior to target lesion. Successful treatment is defined as obtaining < 50% residual stenosis with no serious angiographic complications (e.g., embolism).
  • •Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
  • •Angiographic Exclusion Criteria specific to Iliac Arteries
  • •Target lesion with any aorta involvement.
  • •Angiographic Exclusion Criteria specific to BTK Arteries
  • •Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with < 30% residual stenosis, and no serious angiographic complications (e.g., embolism).
  • •Treatment of vessels below the ankle joint.

结局指标

主要结局

Femoropopliteal Procedural success

Procedural success is defined as residual stenosis < 50% without >= grade D dissections, prior to DCB or stenting for the treated target lesion (core lab assessed).

Iliac Procedural success

Procedural success is defined as residual stenosis < 50% without >= grade D dissections, prior to stenting for the treated target lesion (core lab assessed).

BTK Procedural success

Procedural success is defined as final residual stenosis < 50% without >= grade D dissections for the treated target lesion (core lab assessed).

次要结局

  • Serious angiographic complications(final procedural timepoint)
  • Technical Success (residual stenosis < 50%)(final timepoint (after DCB or stenting))
  • Technical Success (residual stenosis < 30%)(final timepoint (after DCB or stenting))
  • Primary patency(6 and 12 months)
  • Major Adverse Event (MAE)(30 days, 6 and 12 months)
  • Ankle brachial index (ABI) or Toe brachial index (TBI)(30 days, 6, and 12 months)
  • Rutherford Category(30 days, 6, 12 months)

研究者

相似试验

已完成
不适用
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF NIVOLUMAB PLUS IPILIMUMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) CATEGORIZED INTO IMDC INTERMEDIATE/POOR RISKS (J-ENCORE)ADVANCED OR METASTATIC RENAL CELL CARCINOMA
JPRN-UMIN000036772Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.,LTD.286
招募中
不适用
PSR-CRHF: Enlighten Japan
jRCT1042240190Medtronic Japan300
招募中
不适用
Establishment of Japanese-originated comprehensive biomarker system for diagnosis and stratification of patients with various types of dementias based on multicenter alliance for brain biomarkers (MABB)Mild cognitive impairment
JPRN-UMIN000047214Japan Agency for Medical Research and Development240
尚未招募
Unknown
Japanese National RegistryPKD(JRP)autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease
JPRN-jRCT1030230618Muto Satoru1,100
招募中
不适用
HPP JP
jRCT10302407312,000